Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes

FEBS Letters

Volumn 583, Issue 22, 2009, Pages 3718-3724

  Weber, Markus ^a   Sporrer, Daniela ^a   Weigert, Johanna ^a   Wanninger, Josef ^a   Neumeier, Markus ^a   Wurm, Sylvia ^a   Stögbauer, Fabian ^a   Kopp, Andrea ^a   Bala, Margarita ^a   Schäffler, Andreas ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Adiponectin; Galectin 3; Monocyte; Obesity; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; GALECTIN 3; MESSENGER RNA;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; AMINOIMIDAZOLE CARBOXAMIDE; BODY MASS INDEX; CELLS, CULTURED; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTIN 3; HUMANS; IMMUNOBLOTTING; MALE; METFORMIN; MIDDLE AGED; MONOCYTES; OLEIC ACID; PALMITIC ACID; PYRAZOLES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOTIDES; SOLUBILITY; TIME FACTORS;

EID: 71749102818     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.10.008     Document Type: Article

References (44)

1. Adler A.I. Managing diabetes: what to do about cardiovascular disease. Diabet. Res. Clin. Pract. 61 (2003) S3-S8
2. Herder C., Hauner H., Haastert B., Rohrig K., Koenig W., Kolb H., Muller-Scholze S., Thorand B., Holle R., and Rathmann W. Hypoadiponectinemia and proinflammatory state: two sides of the same coin? Results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabet. Care 29 (2006) 1626-1631
3. Ikeda U. Inflammation and coronary artery disease. Curr. Vasc. Pharmacol. 1 (2003) 65-70
4. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue - emerging role in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 273-280
5. Dumic J., Dabelic S., and Flogel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 1760 (2006) 616-635
6. Kim K., Mayer E.P., and Nachtigal M. Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim. Biophys. Acta 1641 (2003) 13-23
7. Elliott M.J., Strasser A., and Metcalf D. Selective up-regulation of macrophage function in granulocyte-macrophage colony-stimulating factor transgenic mice. J. Immunol. 147 (1991) 2957-2963
8. Papaspyridonos M., McNeill E., de Bono J.P., Smith A., Burnand K.G., Channon K.M., and Greaves D.R. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 433-440
9. Fukumori T., Takenaka Y., Yoshii T., Kim H.R., Hogan V., Inohara H., Kagawa S., and Raz A. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63 (2003) 8302-8311
10. Kuwabara I., and Liu F.T. Galectin-3 promotes adhesion of human neutrophils to laminin. J. Immunol. 156 (1996) 3939-3944
11. Elad-Sfadia G., Haklai R., Balan E., and Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 279 (2004) 34922-34930
12. Takenaka Y., Fukumori T., Yoshii T., Oka N., Inohara H., Kim H.R., Bresalier R.S., and Raz A. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol. Cell Biol. 24 (2004) 4395-4406
13. Nachtigal M., Ghaffar A., and Mayer E.P. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am. J. Pathol. 172 (2008) 247-255
14. Mensah-Brown E.P., Al Rabesi Z., Shahin A., Al Shamsi M., Arsenijevic N., Hsu D.K., Liu F.T., and Lukic M.L. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin. Immunol. 130 (2009) 83-88
15. del Pozo V., Rojo M., Rubio M.L., Cortegano I., Cardaba B., Gallardo S., Ortega M., Civantos E., Lopez E., Martin-Mosquero C., Peces-Barba G., Palomino P., Gonzalez-Mangado N., and Lahoz C. Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation. Am. J. Respir. Crit. Care Med. 166 (2002) 732-737
16. Zuberi R.I., Hsu D.K., Kalayci O., Chen H.Y., Sheldon H.K., Yu L., Apgar J.R., Kawakami T., Lilly C.M., and Liu F.T. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am. J. Pathol. 165 (2004) 2045-2053
17. Gavrila A., Chan J.L., Yiannakouris N., Kontogianni M., Miller L.C., Orlova C., and Mantzoros C.S. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J. Clin. Endocrinol. Metab. 88 (2003) 4823-4831
18. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
19. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., Ohashi K., Sakai N., Shimomura I., Kobayashi H., Terasaka N., Inaba T., Funahashi T., and Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
20. Neumeier M., Weigert J., Schaffler A., Wehrwein G., Muller-Ladner U., Scholmerich J., Wrede C., and Buechler C. Different effects of adiponectin isoforms in human monocytic cells. J. Leukoc. Biol. 79 (2006) 803-808
21. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., Kihara S., Funahashi T., Tenner A.J., Tomiyama Y., and Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
22. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 89 (2004) 2563-2568
23. Saijo S., Nagata K., Nakano Y., Tobe T., and Kobayashi Y. Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem. Biophys. Res. Commun. 334 (2005) 1180-1183
24. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., Ishigami M., Kuriyama H., Kishida K., Nishizawa H., Hotta K., Muraguchi M., Ohmoto Y., Yamashita S., Funahashi T., and Matsuzawa Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
25. Weigert J., Neumeier M., Wanninger J., Wurm S., Kopp A., Schober F., Filarsky M., Schaffler A., Zeitoun M., Aslanidis C., and Buechler C. Reduced response to adiponectin and lower abundance of adiponectin receptor proteins in type 2 diabetic monocytes. FEBS Lett. 582 (2008) 1777-1782
26. Tsatsanis C., Zacharioudaki V., Androulidaki A., Dermitzaki E., Charalampopoulos I., Minas V., Gravanis A., and Margioris A.N. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem. Biophys. Res. Commun. 335 (2005) 1254-1263
27. Suzuki S., Wilson-Kubalek E.M., Wert D., Tsao T.S., and Lee D.H. The oligomeric structure of high molecular weight adiponectin. FEBS Lett. 581 (2007) 809-814
28. Tsao T.S., Murrey H.E., Hug C., Lee D.H., and Lodish H.F. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem. 277 (2002) 29359-29362
29. Tang C.H., Chiu Y.C., Tan T.W., Yang R.S., and Fu W.M. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J. Immunol. 179 (2007) 5483-5492
30. Sag D., Carling D., Stout R.D., and Suttles J. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181 (2008) 8633-8641
31. Du J.H., Xu N., Song Y., Xu M., Lu Z.Z., Han C., and Zhang Y.Y. AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem. Biophys. Res. Commun. 337 (2005) 1139-1144
32. Hardie D.G., and Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell?. Eur. J. Biochem. 246 (1997) 259-273
33. Stogbauer F., Neumeier M., Weigert J., Wanninger J., Grandl M., Lehle K., Schmitz G., Aslanidis C., Schaffler A., Scholmerich J., and Buechler C. Highly efficient and low-cost method to isolate human blood monocytes with high purity. J. Immunol. Meth. 337 (2008) 78-80
34. Nam M., Lee W.H., Bae E.J., and Kim S.G. Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition. Arch. Biochem. Biophys. 479 (2008) 74-81
35. Shimada K., Miyazaki T., and Daida H. Adiponectin and atherosclerotic disease. Clin. Chim. Acta 344 (2004) 1-12
36. Gil-Campos M., Canete R.R., and Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr. 23 (2004) 963-974
37. Al-Attas O.S., Al-Daghri N.M., Al-Rubeaan K.A., da Silva N.F., Sabico S.L., Kumar S., McTernan P.G., and Harte A.L. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc. Diabetol. 8 (2009) 20
38. Boden, G. (2008) Obesity and free fatty acids. Endocrinol. Metab. Clin. North Am. 37, 635-646, viii-ix.
39. Alwaili K., Alrasadi K., Awan Z., and Genest J. Approach to the diagnosis and management of lipoprotein disorders. Curr. Opin. Endocrinol. Diabet. Obes. 16 (2009) 132-140
40. Hara K., Horikoshi M., Yamauchi T., Yago H., Miyazaki O., Ebinuma H., Imai Y., Nagai R., and Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabet. Care 29 (2006) 1357-1362
41. Fisher F.F., Trujillo M.E., Hanif W., Barnett A.H., McTernan P.G., Scherer P.E., and Kumar S. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48 (2005) 1084-1087
42. Shim W.S., Kim H.J., Kang E.S., Ahn C.W., Lim S.K., Lee H.C., and Cha B.S. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. Diabet. Res. Clin. Pract. 73 (2006) 284-291
43. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabet. Care 27 (2004) 813-823
44. Joshi N., Caputo G.M., Weitekamp M.R., and Karchmer A.W. Infections in patients with diabetes mellitus. New Engl. J. Med. 341 (1999) 1906-1912